OC 65.1 Long-Term Efficacy and Safety with Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Immune Thrombocytopenia

Autor:	Kuter, D., Efraim, M., Kaplan, Z., Mayer, J., Choi, P., Jansen, G.A.J., McDonald, V., Baker, R., Bird, R., Garg, M., Gumulec, J., Košťál, M., Gernsheimer, T., Ghanima, W., Khan, U., Daak, A., Cooper, N.
Zdroj:	In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Plný text